Dr. Steve Roffler, Professor

Institute of Biomedical Sciences, Academia Sinica
Phone: 886-2-2652-3079
E-mail: sroff@ibms.sinica.edu.tw


Ph.D.@Univ. of California, Berkeley, USA


@We have synthesized glucuronide prodrugs that can be preferentially activated at tumor cells by antibody-enzyme conjugates (immunoenzymes). Current studies are focused on improving the utility of recombinant immunoenzymes by directed molecular evolution and translation of prodrug therapy to the clinic. We are also investigating the efficacy and mode of action of a new glucuronide prodrug of 9-aminocamptothecin that displays good antitumor activity without immunoenzyme pretargeting.

@Another area of interest is the development of novel gene-therapy strategies based on the expression of chimeric proteins on the surface of mammalian cells. We are focusing on the expression of enzymes for prodrug activation and single-chain antibodies for specific regulation of lymphocytes. We are interested in understanding how different domains of chimeric proteins affect their transport and retention on the cell surface.

@We have also developed monoclonal antibodies that identify proteins that are involved in the migration, adhesion and invasion of lung adenocarcinoma cells as well as in the regulation of endothelial cell angiogenesis. Current studies are focused on investigation of protein-protein interactions and signal transduction pathways involved in cancer cell metastasis and angiogenesis.


1. NM Tsai, TL Cheng and SR Roffler. Sensitive quantitation of poly(ethylene glycol)-modified proteins. Biotechniques 30: 396-402, 2001.

2. BM Chen, TL Cheng, SC Tzou and SR Roffler. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy. Int. J. Cancer, 94: 850-858, 2001.

3. JW Chen, K Peck, TM Hong, SC Yang, YP Sher, JY Shih, R Wu, JL Cheng, SR Roffler, CW Wu and PC Yang. Global Analysis of Gene Expression in Invasion by a Lung Cancer Model. Cancer Res., 61: 5223-5230, 2001.

4. KW Liao, WC Chou, YC Lo and SR Roffler. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol Bioeng, 73:313-323, 2001.

5. ZM Prijovich, BM Chen, YL Leu, JW Chern and SR Roffler. Antitumor activity and toxicity of the new glucuronide prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Br. J. Cancer, 86: 1634-1638, 2002.

6. KM Bernt, DS Steinwaerder, S Ni, ZY Li, SR Roffler and A Lieber. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res., 62: 6089-98, 2002.

7. YR Kao, JY Shih, WC Wen, YP Ko, BM Chen, YL Chan, YW Chu, PC Yang, CW Wu and SR Roffler. Tumor-associated antigen L6 (TAL6) and the invasion of human lung cancer cells. Clin. Cancer Res., 9: 2807-2816, 2003.

8. KW Liao, BM Chen, TB Liu, SC Tzo, YM Lin, KF Lin, CI Su and SR Roffler. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of anti-tumor immunity. Cancer Gene Therapy. 10: 779-790, 2003.

9. CH Lo, SC Lee, PY Wu, WY Pan, J Su, CW Cheng, SR Roffler, BL Chiang, CN Lee, CW Wu and MH Tao. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171: 600-607, 2003.

10. ZM Prijovich, YL Leu and SR Roffler. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. Biochem. Pharmacol., 66: 1181-1187, 2003.

Members of Laboratory